2. GPCR/G Protein Immunology/Inflammation Stem Cell/Wnt MAPK/ERK Pathway PI3K/Akt/mTOR
  3. CXCR ERK Akt
  4. BPRCX807

BPRCX 807 is a selective and potent CXCR4 (CXC chemokine receptor type 4) antagonist. BPRCX 807 inhibits CXCL12-mediated ERK and Akt phosphorylation. BPRCX 807 can significantly suppress primary tumor growth. BPRCX 807 can be used for the study of hepatocellular carcinoma.

For research use only. We do not sell to patients.

BPRCX807

BPRCX807 Chemical Structure

CAS No. : 2236595-58-5

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

BPRCX807 Related Antibodies

Top Publications Citing Use of Products

View All CXCR Isoform Specific Products:

View All Isoforms
CXCR CXCR1 CXCR2 CXCR3 CXCR4 CXCR7 CXCR6

View All ERK Isoform Specific Products:

View All Isoforms
ERK ERK1 ERK2 ERK5 ERK8

View All Akt Isoform Specific Products:

View All Isoforms
Akt Akt1 Akt2 Akt3

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

BPRCX 807 is a selective and potent CXCR4 (CXC chemokine receptor type 4) antagonist. BPRCX 807 inhibits CXCL12-mediated ERK and Akt phosphorylation. BPRCX 807 can significantly suppress primary tumor growth. BPRCX 807 can be used for the study of hepatocellular carcinoma[1].

IC50 & Target[1]

CXCR4

 

In Vitro

BPRCX 807 (1.5 h) exhibits an IC50 value of 40.4 nM against HEK293T cells[1].
BPRCX 807 shows an EC50 value of 48.1 nM in CCRF-CEM cells[1].
BPRCX 807 (10 μM, 24-72 h) significantly inhibits CXCL12-induced accelerated wound closure in HCA-1 cells[1].
BPRCX 807 (0.1-1 μM, 17.5 h) significantly reduces the number of migrating HCA-1 cells at a concentration of 1 μM[1].
BPRCX 807 (10-20 μM, 24-48 h) restrains the hypoxia-induced increases in mesenchymal marker expression and alleviates the hypoxia-induced decrease in epithelial markers in HCA-1 cells in a dose-dependent manner[1].
BPRCX 807 (5-20 μM, 24 h) significantly inhibits CXCL12-mediated ERK and Akt phosphorylation in HCA-1 and JHH-7 cells[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

BPRCX807 Related Antibodies

Cell Migration Assay [1]

Cell Line: HCA-1 cells
Concentration: 10 μM
Incubation Time: 0 h, 24 h, 48 h, 72 h
Result: Significantly inhibited CXCL12-induced accelerated wound closure in HCA-1 cells.

Real Time qPCR[1]

Cell Line: Hypoxia-induced HCA-1 cells
Concentration: 10 μM, 20 μM
Incubation Time: 24 h, 48 h
Result: Increased in mesenchymal marker expression (including Slug, Fibronectin, N-cadherin, Vimentin, FOXC2, Zeb1, and Zeb2).
Alleviated the hypoxia-induced decrease in epithelial markers (E-cadherin, MTA-3, CLDN3, and CLDN5).
In Vivo

BPRCX 807 (15 mg/kg, s.c., once daily for 14 days) alone or in combination with Sorafenib (HY-10201) significantly inhibits tumor growth in mouse models of HCA-1 cell allogeneic and JHH-7 cell xenograft[1].
BPRCX 807 (15 mg/kg, s.c., once daily for 14 days), when used in combination with Anti-PD-1, can recruit T cells and synergistically inhibit tumor growth in mice with HCA-1 cell allogeneic transplantation[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: HCA-1 or JHH-7 cells were orally implanted into the livers of 7-week-old C3H/HeNCrNarl mice and 9-week-old BALB/cAnN.Cg Foxnlnu/CrlNarl mice, respectively[1].
Dosage: 15 mg/kg
Administration: S.c., once daily for 14 days
Result: Significantly inhibited tumor growth when used alone.
The effect is strongest when used in combination with sorafenib.
Combined use significantly prolongs overall survival.
Reduced tumor-associated macrophage (TAM) infiltration (F4/80+ cells).
Reprogramed TAMs to the M1 phenotype (increased CD86+) and suppresses the M2 phenotype (decreased CD206+).
Increased cytotoxic CD8+ T cell infiltration.
Animal Model: HCA-1 cells were in situ implanted into 7-week-old C3H/HeNCrNarl mice. For combined anti-PD-1 immunotherapy, mice were intraperitoneally injected with anti-mouse PD-1 antibodies 10 days after tumor implantation[1].
Dosage: 15 mg/kg
Administration: S.c., once daily for 14 days
Result: When used in combination with Anti-PD-1, it significantly increased the infiltration of CD4+ and CD8+ T cells within tumors.
Synergistically inhibited tumor growth (reducing it by 95%) and lung metastasis.
Molecular Weight

613.79

Formula

C31H51N9O4
CAS No.
SMILES

O=C(CNCCC(N1CCC(CC1)NC2=NC(NCC3=NC(CCCNCCCNC4CCCCC4)=CO3)=NC(C)=C2)=O)O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

BPRCX807 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

BPRCX8072236595-58-5BPRCX 807BPRCX-807CXCRERKAktCXC chemokine receptorsC-X-C motif chemokine receptorsExtracellular signal regulated kinasesPKBProtein kinase Bhepatocellular carcinomaCXCR4 receptorprogrammed cell death 1sorafenibtumor microenvironmentInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
BPRCX807
Cat. No.:
HY-178205
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.